CACNA1H and type 2 diabetes mellitus: Based on these results, loganin might decrease CaV3.2 T-type calcium channels and neurotransmitter CGRP distribution in superficial SDH and reduce glial cell activation in PDN rats, related to the improvement of neuropathic pain in T2DM rats.